WHO Issues Conditional Guidelines for GLP-1 therapies in Fight against Global obesity Crisis
Table of Contents
Meta Description: The World Health Organization releases new guidance on GLP-1 therapies like semaglutide and tirzepatide for obesity treatment, acknowledging it as a chronic disease but cautioning on access and long-term effects.
The World Health Organization (WHO) has issued its first-ever guidance on the use of GLP-1 receptor agonists (GLP-1 therapies) for long-term obesity treatment,recognizing the condition as a chronic disease requiring extensive care. The recommendations, while conditional, signal a major shift in how the global health community approaches a crisis affecting over one billion people worldwide and linked to 3.7 million deaths in 2024.
A Growing Global Health Threat
The urgency of the situation is stark. Without important intervention,the WHO warns that the number of people living with obesity could double by 2030,placing an unsustainable burden on healthcare systems and resulting in an estimated $3 trillion in annual economic losses. “Obesity is a major global health challenge,” stated Tedros Adhanom Ghebreyesus,WHO Director-General. “Our new guidance recognises that obesity is a chronic disease that can be treated with comprehensive and lifelong care.While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms.”
Beyond Lifestyle Choices: Understanding Obesity’s Complexity
The WHO emphasizes a critical point: obesity is not simply a matter of personal responsibility or lifestyle choices. It is indeed a complex, chronic condition influenced by a confluence of factors including genetics, environmental influences, biological processes, and social circumstances. This understanding is crucial, as obesity considerably increases the risk of heart disease, type 2 diabetes, certain cancers, and can exacerbate the severity of infectious diseases. For many individuals,achieving and maintaining weight loss proves exceptionally arduous without medical intervention.
How GLP-1 Therapies Work
GLP-1 therapies function by mimicking a natural hormone that regulates appetite, blood sugar levels, and digestion. For individuals struggling with obesity, these medications can facilitate substantial weight loss and improvements in overall health.The WHO added these therapies to its Essential Medicines List in 2025 for the management of type 2 diabetes in high-risk populations, and the new guidelines now extend their recommended long-term use to adults living with obesity, with the exception of pregnant individuals.
Conditional Recommendations and Access Concerns
Despite the potential benefits, the WHO’s recommendation is conditional. This caution stems from limited long-term safety data, uncertainties surrounding the maintenance of weight loss after treatment cessation, the high cost of these medications, and, crucially, significant concerns about equitable access across different countries.
A Multifaceted Approach to Treatment
the WHO stresses that weight-loss medications are not a standalone solution. The most effective treatment strategy combines medication with comprehensive lifestyle changes, including healthier dietary habits, increased physical activity, and ongoing guidance from healthcare professionals. The organization underscores that addressing obesity requires a broad,societal effort,with governments and industry collaborating to create healthier food environments and prioritize early intervention for those at risk.
Addressing supply, Safety, and Equity
Demand for GLP-1 medicines currently far outstrips supply. Even with increased production, the WHO projects that fewer than 10% of eligible individuals will have access to these treatments by 2030. The organization warns that without proactive policies, these therapies could exacerbate existing health inequalities. To expand access, the WHO urges governments to explore strategies such as pooled procurement, fair pricing mechanisms, and voluntary licensing agreements.
Furthermore, the WHO is raising alarms about the increasing circulation of falsified or substandard GLP-1 products, driven by global shortages. Maintaining regulated supply chains, ensuring prescriptions are issued by qualified healthcare providers, and implementing robust oversight are essential to protect patients.
The guidance was developed following requests from Member States and was informed by rigorous scientific evidence, expert review, and valuable input from individuals living with obesity. The WHO plans to update these recommendations as new data emerges and will collaborate with partners in 2026 to prioritize those with the most pressing needs.
